Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 152

1.

Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy.

Shadman M, Gauthier J, Hay KA, Voutsinas JM, Milano F, Li A, Hirayama AV, Sorror ML, Cherian S, Chen X, Cassaday RD, Till BG, Gopal AK, Sandmaier BM, Maloney DG, Turtle CJ.

Blood Adv. 2019 Oct 22;3(20):3062-3069. doi: 10.1182/bloodadvances.2019000593.

2.

Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.

Kim A, Stevenson P, Cassaday RD, Soma L, Fromm JR, Gopal AK, Smith SD, Till B, Lynch RC, Ujjani C, Shadman M, Warren EH, Menon M, Russell K, Tseng YD.

Pract Radiat Oncol. 2019 Oct 1. pii: S1879-8500(19)30277-2. doi: 10.1016/j.prro.2019.09.013. [Epub ahead of print]

PMID:
31585205
3.

Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia.

Vo P, Gooley TA, Rajendran JG, Fisher DR, Orozco JJ, Green DJ, Gopal AK, Haaf R, Nartea M, Storb R, Appelbaum FR, Press OW, Pagel JM, Sandmaier BM.

Haematologica. 2019 Oct 3. pii: haematol.2019.229492. doi: 10.3324/haematol.2019.229492. [Epub ahead of print]

4.

Phase I Study of a CD45-Targeted Antibody-Radionuclide Conjugate for High-Risk Lymphoma.

Cassaday RD, Press OW, Pagel JM, Rajendran JG, Gooley TA, Fisher DR, Holmberg LA, Miyaoka RS, Sandmaier BM, Green DJ, Gopal AK.

Clin Cancer Res. 2019 Sep 3. doi: 10.1158/1078-0432.CCR-19-1567. [Epub ahead of print]

PMID:
31481510
5.

The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model.

O'Steen S, Comstock ML, Orozco JJ, Hamlin DK, Wilbur DS, Jones JC, Kenoyer A, Nartea ME, Lin Y, Miller BW, Gooley TA, Tuazon SA, Till BG, Gopal AK, Sandmaier BM, Press OW, Green DJ.

Blood. 2019 Oct 10;134(15):1247-1256. doi: 10.1182/blood.2019001250.

PMID:
31395601
6.

Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.

Chow VA, Gopal AK, Maloney DG, Turtle CJ, Smith SD, Ujjani CS, Shadman M, Cassaday RD, Till BG, Tseng YD, Warren EH, Shustov AR, Menon MP, Bhark S, Acharya UH, Mullane E, Hannan LM, Voutsinas JM, Gooley TA, Lynch RC.

Am J Hematol. 2019 Aug;94(8):E209-E213. doi: 10.1002/ajh.25505. Epub 2019 May 21. No abstract available.

PMID:
31056762
7.

Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.

Cooper JP, Khajaviyan S, Smith SD, Maloney DG, Shustov AR, Warren EH, Soma LA, Lynch RC, Ujjani C, Till B, Halpern AB, Gopal AK, Deeg HJ, Scott BL, Shadman M.

Clin Lymphoma Myeloma Leuk. 2019 Jun;19(6):390-395. doi: 10.1016/j.clml.2019.03.003. Epub 2019 Mar 11.

PMID:
30948330
8.

Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal.

Li A, Wu Q, Davis C, Kirtane KS, Pham PD, Sorror ML, Lee SJ, Gopal AK, Dong JF, Garcia DA, Weiss NS, R Hingorani S.

Biol Blood Marrow Transplant. 2019 Mar;25(3):570-576. doi: 10.1016/j.bbmt.2018.10.015. Epub 2018 Oct 26.

PMID:
30940363
9.

Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.

Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP.

J Clin Oncol. 2019 Jul 20;37(21):1790-1799. doi: 10.1200/JCO.18.01994. Epub 2019 Apr 2.

10.

Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.

Salles G, Gopal AK, Minnema MC, Wakamiya K, Feng H, Schecter JM, Wang M.

Clin Lymphoma Myeloma Leuk. 2019 May;19(5):275-284. doi: 10.1016/j.clml.2018.12.013. Epub 2019 Jan 2.

PMID:
30795996
11.

Eligibility for CAR T-cell therapy: An analysis of selection criteria and survival outcomes in chemorefractory DLBCL.

Smith SD, Reddy P, Sokolova A, Chow VA, Lynch RC, Shadman MA, Till BG, Shustov AR, Warren EH, Ujjani CS, Menon MP, Tseng YD, Gopal AK.

Am J Hematol. 2019 Apr;94(4):E117-E116. doi: 10.1002/ajh.25411. Epub 2019 Feb 4. No abstract available.

PMID:
30663774
12.

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.

Ramchandren R, Advani RH, Ansell SM, Bartlett NL, Chen R, Connors JM, Feldman T, Forero-Torres A, Friedberg JW, Gopal AK, Gordon LI, Kuruvilla J, Savage KJ, Younes A, Engley G, Manley TJ, Fenton K, Straus DJ.

Clin Cancer Res. 2019 Mar 15;25(6):1718-1726. doi: 10.1158/1078-0432.CCR-18-2435. Epub 2019 Jan 7.

PMID:
30617130
13.

Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.

Budde LE, Wu D, Martin DB, Philip M, Shustov AR, Smith SD, Gooley TA, Chen TL, Libby EN, Chen EY, Kojouri K, Langerak A, Roden JE, Press OW, Gopal AK.

Br J Haematol. 2018 Nov;183(4):601-607. doi: 10.1111/bjh.15585. Epub 2018 Sep 14.

14.

A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks.

Poston JN, Fromm JR, Rasmussen HA, Shustov AR, Libby EN 3rd, Smith SD, Gooley T, Gopal AK.

Br J Haematol. 2019 Jul;186(1):159-162. doi: 10.1111/bjh.15742. Epub 2018 Dec 28. No abstract available.

PMID:
30592026
15.

Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma.

Puronen CE, Cassaday RD, Stevenson PA, Sandmaier BM, Flowers ME, Green DJ, Maloney DG, Storb RF, Press OW, Gopal AK.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2211-2215. doi: 10.1016/j.bbmt.2018.06.033. Epub 2018 Jul 3.

16.

Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma.

Smith SD, Gandhy S, Gopal AK, Reddy P, Shadman M, Till BG, Lynch RC, Kanan S, Cowan A, Low L, Hill BT.

Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):48-52. doi: 10.1016/j.clml.2018.10.006. Epub 2018 Oct 17.

PMID:
30409719
17.

Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma.

Greenbaum AM, Green DJ, Holmberg LA, Gooley T, Till BG, Budde LE, Rasmussen H, Press OW, Gopal AK.

Blood Res. 2018 Sep;53(3):223-226. doi: 10.5045/br.2018.53.3.223. Epub 2018 Sep 28.

18.

Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.

Chow VA, Shadman M, Gopal AK.

Blood. 2018 Aug 23;132(8):777-781. doi: 10.1182/blood-2018-04-839217. Epub 2018 Jun 18. Review.

19.

Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.

Gopal AK, Schuster SJ, Fowler NH, Trotman J, Hess G, Hou JZ, Yacoub A, Lill M, Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Caballero D, Deshpande S, Gartenberg GJ, Wang SS, Damle RN, Schaffer M, Balasubramanian S, Vermeulen J, Cheson BD, Salles G.

J Clin Oncol. 2018 Aug 10;36(23):2405-2412. doi: 10.1200/JCO.2017.76.8853. Epub 2018 May 31.

PMID:
29851546
20.

Have we found the right patient population for transplantation in follicular lymphoma?

Lynch RC, Gopal AK.

Cancer. 2018 Jun 15;124(12):2484-2487. doi: 10.1002/cncr.31376. Epub 2018 Apr 12. No abstract available.

21.

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.

Segal NH, He AR, Doi T, Levy R, Bhatia S, Pishvaian MJ, Cesari R, Chen Y, Davis CB, Huang B, Thall AD, Gopal AK.

Clin Cancer Res. 2018 Apr 15;24(8):1816-1823. doi: 10.1158/1078-0432.CCR-17-1922. Epub 2018 Mar 16.

22.

Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.

Cowan AJ, Stevenson PA, Libby EN, Becker PS, Coffey DG, Green DJ, Hyun TS, Fromm JR, Gopal AK, Holmberg LA.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1386-1391. doi: 10.1016/j.bbmt.2018.02.017. Epub 2018 Mar 1.

23.

R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.

Barr PM, Li H, Burack WR, LeBlanc M, Smith SM, Gopal AK, Floyd JD, Persky DO, Press OW, Fisher RI, Friedberg JW.

Lancet Haematol. 2018 Mar;5(3):e102-e108. doi: 10.1016/S2352-3026(18)30001-2. Epub 2018 Jan 26.

24.

Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.

Shadman M, Li H, Rimsza L, Leonard JP, Kaminski MS, Braziel RM, Spier CM, Gopal AK, Maloney DG, Cheson BD, Dakhil S, LeBlanc M, Smith SM, Fisher RI, Friedberg JW, Press OW.

J Clin Oncol. 2018 Mar 1;36(7):697-703. doi: 10.1200/JCO.2017.74.5083. Epub 2018 Jan 22.

25.

Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation.

Li A, Davis C, Wu Q, Li S, Kesten MF, Holmberg LA, Gopal AK, Garcia DA.

Blood Adv. 2017 Apr 27;1(12):707-714. doi: 10.1182/bloodadvances.2017006130. eCollection 2017 May 9.

26.

Long-term results of a sirolimus-eluting stent with biodegradable polymer (RAPSTROM™) in de novo coronary stenoses.

Figini F, Manjunath CN, Srinivas BC, Sadananda KS, Sreedharan M, Fischer L, Pillai R, Varghese K, Gopal AK, Nagesh CM, Sheiban I.

Cardiovasc Revasc Med. 2018 Jun;19(4):429-432. doi: 10.1016/j.carrev.2017.10.003. Epub 2017 Oct 7.

PMID:
29174500
27.

CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.

Green DJ, O'Steen S, Lin Y, Comstock ML, Kenoyer AL, Hamlin DK, Wilbur DS, Fisher DR, Nartea M, Hylarides MD, Gopal AK, Gooley TA, Orozco JJ, Till BG, Orcutt KD, Wittrup KD, Press OW.

Blood. 2018 Feb 8;131(6):611-620. doi: 10.1182/blood-2017-09-807610. Epub 2017 Nov 20.

28.

Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.

Tseng YD, Stevenson PA, Cassaday RD, Cowan A, Till BG, Shadman M, Graf SA, Ermoian R, Smith SD, Holmberg LA, Press OW, Gopal AK.

Biol Blood Marrow Transplant. 2018 Feb;24(2):282-287. doi: 10.1016/j.bbmt.2017.10.029. Epub 2017 Oct 20.

29.

Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation.

Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1826-1838. doi: 10.1016/j.bbmt.2017.07.027. Epub 2017 Aug 7.

30.

Venetoclax Synergizes with Radiotherapy for Treatment of B-cell Lymphomas.

O'Steen S, Green DJ, Gopal AK, Orozco JJ, Kenoyer AL, Lin Y, Wilbur DS, Hamlin DK, Fisher DR, Hylarides MD, Gooley TA, Waltman A, Till BG, Press OW.

Cancer Res. 2017 Jul 15;77(14):3885-3893. doi: 10.1158/0008-5472.CAN-17-0082. Epub 2017 May 31.

31.

Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma.

Gopal AK, Fanale MA, Moskowitz CH, Shustov AR, Mitra S, Ye W, Younes A, Moskowitz AJ.

Ann Oncol. 2017 May 1;28(5):1057-1063. doi: 10.1093/annonc/mdx028.

32.

Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy.

Gopal AK, Kahl BS, Flowers CR, Martin P, Ansell SM, Abella-Dominicis E, Koh B, Ye W, Barr PM, Salles GA, Friedberg JW.

Blood. 2017 Jun 1;129(22):3037-3039. doi: 10.1182/blood-2016-12-757740. Epub 2017 Mar 21. No abstract available.

PMID:
28325864
33.

Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature Review.

Potts DA, Fromm JR, Gopal AK, Cassaday RD.

Case Rep Hematol. 2017;2017:2676254. doi: 10.1155/2017/2676254. Epub 2017 Feb 21.

34.

Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma.

Yan F, Gopal AK, Graf SA.

Pharmaceuticals (Basel). 2017 Mar 10;10(1). pii: E28. doi: 10.3390/ph10010028. Review.

35.

Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy.

Floeter AE, Patel A, Tran M, Chamberlain MC, Hendrie PC, Gopal AK, Cassaday RD.

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):225-230. doi: 10.1016/j.clml.2016.12.004. Epub 2017 Jan 10.

PMID:
28169156
36.

Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications.

Mostaghel EA, Martin PS, Mongovin S, Frayo S, Zhang A, Edlefsen KL, Press OW, Gopal AK.

Exp Hematol. 2017 May;49:34-38.e2. doi: 10.1016/j.exphem.2017.01.001. Epub 2017 Jan 21.

37.

Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma.

Cowan AJ, Stevenson PA, Gooley TA, Frayo SL, Oliveira GR, Smith SD, Green DJ, Roden JE, Pagel JM, Wood BL, Press OW, Gopal AK.

Br J Haematol. 2017 Feb;176(4):583-590. doi: 10.1111/bjh.14451. Epub 2017 Jan 5.

38.

Recommendations for Clinical Trial Development in Mantle Cell Lymphoma.

Spurgeon SE, Till BG, Martin P, Goy AH, Dreyling MP, Gopal AK, LeBlanc M, Leonard JP, Friedberg JW, Baizer L, Little RF, Kahl BS, Smith MR.

J Natl Cancer Inst. 2016 Dec 31;109(1). doi: 10.1093/jnci/djw263. Print 2017 Jan. Review.

39.

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study.

Salles G, Schuster SJ, de Vos S, Wagner-Johnston ND, Viardot A, Blum KA, Flowers CR, Jurczak WJ, Flinn IW, Kahl BS, Martin P, Kim Y, Shreay S, Will M, Sorensen B, Breuleux M, Zinzani PL, Gopal AK.

Haematologica. 2017 Apr;102(4):e156-e159. doi: 10.3324/haematol.2016.151738. Epub 2016 Dec 15. No abstract available.

40.

Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.

Cowan AJ, Klippel ZK, Stevenson PA, Hyun TS, Tuazon S, Becker PS, Green DJ, Holmberg LA, Coffey DG, Gopal AK, Libby EN.

Amyloid. 2016 Dec;23(4):254-259. Epub 2016 Nov 23.

41.

Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.

Green DJ, Frayo SL, Lin Y, Hamlin DK, Fisher DR, Frost SH, Kenoyer AL, Hylarides MD, Gopal AK, Gooley TA, Orozco JJ, Till BG, O'Steen S, Orcutt KD, Wilbur DS, Wittrup KD, Press OW.

Cancer Res. 2016 Nov 15;76(22):6669-6679. doi: 10.1158/0008-5472.CAN-16-0571. Epub 2016 Sep 2.

42.

Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas.

Gauthier J, Holmberg L, Wu D, Bensinger W, Gopal AK, Press O, Maloney D, Green DJ, Till BG, Byelykh D, Shustov A.

Bone Marrow Transplant. 2016 Dec;51(12):1617-1619. doi: 10.1038/bmt.2016.227. Epub 2016 Oct 24. No abstract available.

PMID:
27775693
43.

Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.

Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, Connors JM, Engert A, Larsen EK, Huebner D, Fong A, Younes A.

Blood. 2016 Sep 22;128(12):1562-6. doi: 10.1182/blood-2016-02-699850. Epub 2016 Jul 18.

44.

Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma.

Graf SA, Vaughn JE, Chauncey TR, Storer BE, Gopal AK, Holmberg LA, McCune JS, Bensinger WI, Maloney DG, Press OW, Storb R, Sorror ML.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1582-1587. doi: 10.1016/j.bbmt.2016.06.007. Epub 2016 Jun 14.

45.

Bendamustine, etoposide and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in patients with multiple myeloma.

Green DJ, Bensinger WI, Holmberg LA, Gooley T, Till BG, Budde LE, Pagel JM, Frayo SL, Roden JE, Hedin L, Press OW, Gopal AK.

Bone Marrow Transplant. 2016 Oct;51(10):1330-1336. doi: 10.1038/bmt.2016.123. Epub 2016 May 23.

46.

Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.

Rufener GA, Press OW, Olsen P, Lee SY, Jensen MC, Gopal AK, Pender B, Budde LE, Rossow JK, Green DJ, Maloney DG, Riddell SR, Till BG.

Cancer Immunol Res. 2016 Jun;4(6):509-19. doi: 10.1158/2326-6066.CIR-15-0276. Epub 2016 Apr 21.

47.

Response assessment in lymphoma: Concordance between independent central review and local evaluation in a clinical trial setting.

Gopal AK, Pro B, Connors JM, Younes A, Engert A, Shustov AR, Chi X, Larsen EK, Kennedy DA, Sievers EL.

Clin Trials. 2016 Oct;13(5):545-54. doi: 10.1177/1740774516645338. Epub 2016 May 5.

48.

Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.

Zhao B, Chen R, O'Connor OA, Gopal AK, Ramchandren R, Goy A, Matous JV, Fasanmade AA, Manley TJ, Han TH.

Br J Clin Pharmacol. 2016 Sep;82(3):696-705. doi: 10.1111/bcp.12988. Epub 2016 May 29.

49.

Idelalisib for the treatment of non-Hodgkin lymphoma.

Graf SA, Gopal AK.

Expert Opin Pharmacother. 2016;17(2):265-74. doi: 10.1517/14656566.2016.1135130. Epub 2016 Jan 28. Review.

50.

Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment.

Orozco JJ, Kenoyer A, Balkin ER, Gooley TA, Hamlin DK, Wilbur DS, Hylarides MD, Frost SH, Mawad R, O'Donnell P, Sandmaier BM, Fuchs EJ, Luznik L, Green DJ, Gopal AK, Press OW, Pagel JM.

Blood. 2016 Jan 21;127(3):352-9. doi: 10.1182/blood-2014-12-617019. Epub 2015 Nov 17.

Supplemental Content

Loading ...
Support Center